Opportunity Information: Apply for PAR 16 041
Apply for PAR 16 041
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Drug Discovery For Nervous System Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.273, 93.279,.
- This funding opportunity was created on Nov 24, 2015 and posted on Nov 24, 2015.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Drug Discovery For Nervous System Disorders (R01) is a National Institutes of Health (NIH) funding opportunity (Agency: HHS-NIH11) that supports research projects aimed at discovering and running preclinical tests on new therapeutic compounds for nervous system disorders. The program uses the R01 research project grant mechanism, meaning it is designed for hypothesis-driven, multi-year research efforts where the applicant proposes a clear scientific plan, milestones, and a strategy for generating strong preclinical evidence that a candidate compound could be useful for preventing or treating a neurological condition. The overall emphasis is on moving from compound discovery into preclinical validation, so the work is expected to go beyond basic biology and into activities that help position a compound for later-stage development.
The central goal of the announcement is to encourage applications that identify novel compounds and evaluate them in preclinical settings relevant to nervous system disease. In practical terms, this can include identifying or designing small molecules or other therapeutic modalities, establishing assays to test activity, demonstrating target engagement or mechanism, optimizing promising leads, and conducting proof-of-concept studies in appropriate cellular or animal models. A key theme is translational relevance: applicants are generally expected to build a coherent path from discovery to preclinical testing that supports the rationale for why the compound might ultimately work in people, even though the FOA is focused on discovery and preclinical stages rather than clinical trials.
The opportunity is categorized as discretionary funding and is listed under the broad activity areas of education and health, reflecting NIH's mission-driven research support. It is associated with CFDA numbers 93.242, 93.273, and 93.279, which correspond to NIH program areas that fund biomedical and behavioral research. The FOA was posted and created on November 24, 2015, and the listed closing date for the version provided is January 7, 2019.
Eligibility is broad and includes a wide range of domestic applicant organizations. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations both with and without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; small businesses; and other entities as allowed under the NIH eligibility guidance referenced in the FOA. This wide eligibility means proposals can come from academic labs, research institutes, nonprofits, biotech and pharmaceutical companies, small businesses, and government-affiliated research entities, as long as they meet NIH requirements.
From an applicant standpoint, the most important takeaway is that this FOA is meant to fund actionable drug discovery and preclinical development work for nervous system disorders, using an R01 structure that typically expects a well-justified, rigorous experimental plan and clear deliverables. While the source summary does not list an award ceiling or expected number of awards, the intent is clearly to support research that generates credible preclinical evidence for novel compounds that could become future therapies for neurological diseases.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled Drug Discovery For Nervous System Disorders (R01).
Which agency is offering this grant?
This is a National Institutes of Health (NIH) funding opportunity under HHS-NIH11.
What is the main purpose of this FOA?
The central goal is to support research projects that discover novel therapeutic compounds and evaluate them through preclinical testing for nervous system disorders. The emphasis is on moving beyond basic biology into activities that help position a candidate compound for later-stage development.
What grant mechanism does this program use?
The program uses the R01 research project grant mechanism, which is designed for hypothesis-driven, multi-year research where the applicant proposes a clear scientific plan, milestones, and a strategy to generate strong preclinical evidence.
What stage of research does this opportunity support?
It supports work from compound discovery through preclinical validation. The focus is on generating credible preclinical evidence that a compound could be useful for preventing or treating a neurological condition.
Is the focus more on basic science or translational research?
The emphasis is on translational relevance. Projects are expected to go beyond basic biology and build a coherent path from discovery into preclinical testing that supports the rationale for potential future use in people.
Does this FOA support clinical trials?
Based on the provided information, the FOA is focused on discovery and preclinical stages rather than clinical trials.
What kinds of activities or tasks are considered in-scope?
Examples of in-scope activities include:
- Identifying or designing small molecules or other therapeutic modalities
- Establishing assays to test activity
- Demonstrating target engagement or mechanism
- Optimizing promising leads
- Conducting proof-of-concept studies in appropriate cellular or animal models
What disease area does this program target?
The program targets nervous system disorders, with the goal of generating candidate therapeutic compounds and preclinical evidence relevant to neurological conditions.
What does the FOA expect from applicants in terms of project structure?
The R01 structure described in the summary indicates applicants should propose a clear scientific plan, include milestones, and describe a strategy for producing strong preclinical evidence supporting the candidate compound.
What does "preclinical validation" mean in the context of this FOA?
In this opportunity, preclinical validation refers to generating evidence in relevant cellular or animal models (and related supporting studies like assays and target engagement) to show a candidate compound has potential to prevent or treat a nervous system disorder.
What type of funding is this categorized as?
The opportunity is categorized as discretionary funding.
What broad activity areas does it fall under?
It is listed under the broad activity areas of education and health, consistent with NIH mission-driven research support.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.242, 93.273, and 93.279.
When was this FOA posted/created?
The FOA was posted and created on November 24, 2015.
What is the closing date listed for the version provided?
The listed closing date for the version provided is January 7, 2019.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic applicant organizations, including:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Other Native American tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits with 501(c)(3) status (excluding higher education institutions in that nonprofit category)
- Nonprofits without 501(c)(3) status (excluding higher education institutions in that nonprofit category)
- For-profit organizations other than small businesses
- Small businesses
- Other entities as allowed under NIH eligibility guidance referenced in the FOA
Can academic institutions apply?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Can companies apply (biotech/pharma or other for-profits)?
Yes. Eligibility includes for-profit organizations other than small businesses and also small businesses, as long as they meet NIH requirements.
Can nonprofits apply?
Yes. Eligibility includes nonprofit organizations with and without 501(c)(3) status (with the caveat noted in the summary excluding higher education institutions within those nonprofit categories).
Can tribal organizations apply?
Yes. Eligibility includes federally recognized Native American tribal governments and other tribal organizations.
Can government-affiliated entities apply?
Yes. Eligibility includes multiple government entity types (state, county, city/township, special district) and also includes public housing authorities/Indian housing authorities.
What is the most important takeaway for applicants?
The key point is that this FOA is meant to fund actionable drug discovery and preclinical development work for nervous system disorders, using an R01 format that expects a rigorous plan, milestones, and clear deliverables aimed at producing credible preclinical evidence for a novel compound.
Is there an award ceiling or a stated number of awards?
The provided summary does not list an award ceiling or an expected number of awards.
What kinds of applicants is this designed for in practice?
Because eligibility is broad, proposals may come from academic labs, research institutes, nonprofits, biotech and pharmaceutical companies, small businesses, and government-affiliated research entities, as long as NIH requirements are met.
Browse more opportunities from the same category: Education, Health
Next opportunity: Planning Grant for Emerging Epidemic Virus Research Training for West African Countries with Widespread Transmission of Ebola- Guinea, Liberia, and Sierra Leone (D71)
Previous opportunity: Corridor/Greenway Trail Rehabilitation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 041
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 041) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV/AIDS High Priority Drug Abuse Research (R01) Apply for PAS 16 018 Funding Number: PAS 16 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 012 Funding Number: RFA DA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 16 074 Funding Number: PA 16 074 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $50,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 041", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.